ChemoCentryx Stock Forecast, Price & News

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

Is ChemoCentryx a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ChemoCentryx stock.
View analyst ratings for ChemoCentryx or view top-rated stocks.

How has ChemoCentryx's stock price been impacted by COVID-19?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CCXI stock has decreased by 39.7% and is now trading at $25.06.
View which stocks have been most impacted by COVID-19.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for ChemoCentryx.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.13. The biopharmaceutical company earned $17.74 million during the quarter, compared to analyst estimates of $14.70 million. ChemoCentryx had a negative net margin of 353.41% and a negative trailing twelve-month return on equity of 34.78%. During the same period last year, the firm earned ($0.35) earnings per share.
View ChemoCentryx's earnings history.

What price target have analysts set for CCXI?

6 equities research analysts have issued 12-month price targets for ChemoCentryx's stock. Their forecasts range from $38.00 to $110.00. On average, they expect ChemoCentryx's stock price to reach $75.00 in the next year. This suggests a possible upside of 199.3% from the stock's current price.
View analysts' price targets for ChemoCentryx or view top-rated stocks among Wall Street analysts.

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:

• Thomas J. Schall, Chairman, President & Chief Executive Officer
• Tausif Butt, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
• Susan M. Kanaya, Chief Financial Officer, Secretary & Director
• Rita I. Jain, Chief Medical Officer, Executive Director & EVP
• Sangita Ghosh, Senior Vice President-Technical Operations

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ChemoCentryx's key competitors?

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Arena Pharmaceuticals (ARNA).
View all of CCXI's competitors.

What other stocks do shareholders of ChemoCentryx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR).

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends for ChemoCentryx.

Which major investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, and Thomas A Edwards.
View insider buying and selling activity for ChemoCentryx or view top insider-selling stocks.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $25.06.

How much money does ChemoCentryx make?

ChemoCentryx has a market capitalization of $1.75 billion and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55.36 million in net income (profit) each year or ($1.74) on an earnings per share basis.

How many employees does ChemoCentryx have?

ChemoCentryx employs 133 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

Where are ChemoCentryx's headquarters?

ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at [email protected], or via fax at 650-210-2910.